Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Longeveron Inc

LGVN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$6.81

▲ +3.50%

Market Cap $21.71M · Vol 15.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$21.71M

Micro Cap

Div Yield

N/A

EPS Growth

+44.70%

YoY

RSI (14)

32.13

Momentum

Beta

-0.27

vs Market

52W High

$12.20

44.18% below

52W Low

$4.75

43.34% above

Volume

15.39K

Avg 10.71K

P/B

2.04

Price-to-book

ROE

N/A

Return on equity

Free Float

84.86%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Longeveron Inc (LGVN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LGVN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.34%

-8.23%

-14.88%

+29.81%

YTD

+34.58%

-8.97%

-97.34%

-98.18%

Financials & Valuation

TTM · Annual

Total Revenue	$1.20M
Net Income	$-22,704,000.00
Revenue Growth (YoY)	-9.18%
Gross Margin	66.97%
Operating Margin	-1,942.20%
Net Profit Margin	-1,893.58%
ROE	N/A
ROA · ROIC	-126.77% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.42
P/B	2.04
P/FCF	N/A
EPS Growth	+44.70%
Outstanding Shares	3.19M

Technical Indicators

50-Day SMA	$6.91
200-Day SMA	$7.20
RSI (14)	32.13
Beta	-0.27
52-Week High	$12.20
52-Week Low	$4.75

Volume Today	15.39K
Avg Daily Volume (30D)	10.71K
Relative Volume	1.44x
Volatility (10D)	105.66
Volatility (30D)	94.51
Free Float	84.86%

Analyst Consensus

BUY

Current Price $6.81

Mean Target $55.00

52W Low$4.75 52W High$12.20

Current

Target

$4.75 $12.20

Current Analyst target

+707.64% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00YZ6JJN6

ISINUS54303L2034

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% RVMD Revolution Medicines Inc -0.40% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66%

Company Profile

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.